Overview
Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.
Eligibility
Inclusion Criteria:
- Patient over 18
- Patient affiliated to a social security scheme
- Patient who understands French
- Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old.
- Patient with active cancer:
- Cancer treatment within the last 6 months,
- Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer.
- The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy).
- Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)
Exclusion Criteria:
- Patients under legal protection
- Patients with concomitant pulmonary embolism
- Patient with proximal or distal deep vein thrombosis
- Patient treated with anticoagulant therapy for another indication
- Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding.
- Patient opposed to participation in research